Introduction
The reporting of suspected adverse drug reactions cant determinants of reporting rates [2] [3] [4] . The present (ADRs) to the Committee on Safety of Medicines survey was conducted in order to assess the attitudes (CSM) is fundamental to the safety surveillance of of UK doctors to the CSM's yellow card scheme so as marketed medicines. Notwithstanding the success of to identify reasons for under-reporting and to deterthe 'yellow card' reporting scheme, however, only a mine what steps might be effective in increasing small proportion of even severe ADRs are notified [1] . reporting rates. Similar surveys, using the same quesAccumulating evidence suggests that doctors' attitionnaire, are being conducted in other member states tudes to national ADR reporting schemes are signifi-of the European Union. (Table 3 ). The first two items were designed to ascertain whether reporting forms were available when needed, and whether the disclosure of confidential information inhibited reporting. Whilst the former appeared to be a significant deterrent, the latter did not. The remaining seven items in question 3 sought to determine whether Inman's 'seven deadly sins' [5] inhibited reporting. These comprise ignorance ('I am unsure how to report and ADR'), diffidence ('I may appear foolish about reporting a suspected ADR'), fear ('I may expose myself to legal liability by reporting an ADR'), lethargy ('I am too busy to report ADRs'), guilt ('I am reluctant to admit I may have caused harm'), ambition ('I would rather collect cases and publish them') and complacency ('only safe drugs are marketed'). Of these only lethargy appeared to inhibit, significantly, ADR reporting.
In question 4 respondents were asked about the significance of the black triangle (V) that appears on data sheets, in MIMS, the British National Formulary and advertising literature for new products. The majority (64%) knew that the symbol signified that all suspected reactions to the product should be reported although a higher proportion of general practitioners responded correctly (77%) compared with hospital doctors (55%). Only 48% of respondents knew that the black triangle indicated a new drug and overall only 39% answered both parts of the question correctly. Again, general practitioners were better informed than hospital doctors with 46% and 35% (respectively) answering both parts correctly.
Question 5 sought respondents' views on the types of problems for which the CSM seeks ADR reports ( (Table 5) . Although most respondents recognised that the scheme was intended to identify previously unrecognised reactions to drugs, there was a lesser appreciation that it was also able to identify predisposing factors, and characterise reactions. 
Discussion
There has, previously, been only one attempt to ascertain the attitudes of the British medical profession to the CSM's 'yellow card scheme' [4] . That study, conducted amongst doctors practising in circumscribed areas in the north-east of England, was designed to compare attitudes amongst doctors in Health Authorities with divergent reporting rates. By contrast, the present investigation was designed as a national survey to assess attitudes to, and understanding of, the UK spontaneous reporting scheme by doctors generally.
The overall response rate (57%) was disappointing. The response rate was particularly poor for those graduating after 1987 and this probably reflects the difficulty in locating mobile trainees, either in hospitals or in general practice, from addresses in the Medical Directory. The difference in the median year of graduation of responders (1975) and non-responders (1979) is a reflection of this. The response rate for doctors graduating in the 1960s was correspondingly higher. Notwithstanding the problems that arise in interpreting the responses to the present questionnaire, a number of important points emerge.
First, 63% of responders claimed to have reported an ADR to either the CSM (via a yellow card) or to a manufacturer (who has a statutory obligation to pass the information to the Medicines Control Agency). This is substantially in excess of a previous estimate (16%) [6] of the proportion of doctors who have 'ever' submitted a report of an ADR. Even if none of the non-responders had 'ever' reported an ADR, the proportion of reporters amongst the UK medical profession (37%) is more than double that of the only previous estimate. The higher proportion of general practitioners who claimed to have sent ADR reports to the CSM, when compared with hospital doctors, is concordant with the observation that more than twothirds of the total number of yellow cards received come from general practitioners. The smaller proportion of doctors who claim to report directly to pharmaceutical companies, compared with those reporting directly to the CSM, is again consistent with the fact that 85-90% of all yellow cards are derived directly from the medical profession.
Second, responders generally had a good appreciation of the objectives of the 'yellow card' scheme and were positive about its importance in monitoring the safety of marketed medicines. Overall, however, doctors in general practice were more aware of the criteria for reporting ADRs than their colleagues in hospital practice. This confirms the results of the previous attitudinal survey of doctors in the UK [4] . It emphasises the need to develop a more robust ADR reporting culture amongst hospital doctors particularly in view of the fact that patients with the most severe ADRs are likely to present to hospital.
Third, the survey failed to substantiate that six of the seven 'traditional' reasons [5] given for failing to report ADRs are, in fact, deterrents to reporting. There was however a clear indication that a heavy work-load deterred ADR reporting (Table 3 ) amongst both general practitioners (27%) and hospital doctors (17%). This, again, is concordant with the previous UK study [4] .
Fourthly, the survey elucidated at least some of the factors that inhibit yellow card reporting. Lack of confidence in an iatrogenic diagnosis, especially amongst hospital doctors, appears to deter reporting ( Table 2 ). The CSM wishes to receive reports of suspected ADRs as well as proven ones. Unavailability of report forms (Table 3) apparently limits reporting by doctors generally though these are interleaved in the British National Formulary, the Data Sheet Compendium, the OTC directory, MIMS and FPIO prescription pads. However the gradual disappearance of the last of these, with increasing use of computerised prescribing stationery, may have had a detrimental effect on reporting by general practitioners. Although almost all respondents appreciated that the yellow card scheme acts as an 'early warning system' (Table  5 ) they were less aware of its other roles. Finally, the precise meaning of the black triangle (V) symbol that appears in prescribing literature and promotional material was not known by over half of all responders.
In conclusion, whilst the medical profession is generally supportive of the CSM's yellow card scheme there are a number of areas of misunderstanding which may contribute to under-reporting. Most important of all, however, is the need to ensure that an ADR reporting culture pervades the profession as a whole.
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